Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Approved in Europe for Nonsquamous NSCLC

Sep 6, 2019 – The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR or ALK molecular aberrations, according to Roche (Genentech) the developer of the PD-L1 inhibitor. The approval was based on data from the phase III IMpower130 study, which showed that the combination of … (leggi tutto)